Casdin Partners Master Fund, L.p. - Net Worth and Insider Trading
Casdin Partners Master Fund, L.p. Net Worth
The estimated net worth of Casdin Partners Master Fund, L.p. is at least $463 Million dollars as of 2024-10-01. Casdin Partners Master Fund, L.p. is the 10% Owner of BioLife Solutions Inc and owns about 8,707,165 shares of BioLife Solutions Inc (BLFS) stock worth over $218 Million. Casdin Partners Master Fund, L.p. is the Director, 10% Owner of Standard BioTools Inc and owns about 74,036,109 shares of Standard BioTools Inc (LAB) stock worth over $143 Million. Casdin Partners Master Fund, L.p. is also the 10% Owner of MaxCyte Inc and owns about 10,000,000 shares of MaxCyte Inc (MXCT) stock worth over $39 Million. Besides these, Casdin Partners Master Fund, L.p. also holds Absci Corp (ABSI) , Verve Therapeutics Inc (VERV) , 2seventy bio Inc (TSVT) , Decibel Therapeutics Inc (DBTX) , Constellation Pharmaceuticals Inc (CNST) , Fulcrum Therapeutics Inc (FULC) . Details can be seen in Casdin Partners Master Fund, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Casdin Partners Master Fund, L.p. has not made any transactions after 2024-08-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Casdin Partners Master Fund, L.p.
Casdin Partners Master Fund, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Casdin Partners Master Fund, L.p. owns 10 companies in total, including BioLife Solutions Inc (BLFS) , Fulcrum Therapeutics Inc (FULC) , and Constellation Pharmaceuticals Inc (CNST) among others .
Insider Ownership Summary of Casdin Partners Master Fund, L.p.
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
BLFS | BioLife Solutions Inc | 2023-10-19 | 10 percent owner |
FULC | Fulcrum Therapeutics Inc | 2019-07-22 | 10 percent owner |
CNST | Constellation Pharmaceuticals Inc | 2018-07-23 | 10 percent owner |
2024-08-27 | director & 10 percent owner | ||
2022-10-03 | 10 percent owner | ||
2021-02-17 | 10 percent owner | ||
2021-07-26 | director & 10 percent owner | ||
2021-06-21 | 10 percent owner | ||
2021-07-29 | 10 percent owner | ||
2023-01-31 | director & 10 percent owner |
Casdin Partners Master Fund, L.p. Latest Holdings Summary
Casdin Partners Master Fund, L.p. currently owns a total of 9 stocks. Among these stocks, Casdin Partners Master Fund, L.p. owns 8,707,165 shares of BioLife Solutions Inc (BLFS) as of October 19, 2023, with a value of $218 Million and a weighting of 47.04%. Casdin Partners Master Fund, L.p. owns 74,036,109 shares of Standard BioTools Inc (LAB) as of August 27, 2024, with a value of $143 Million and a weighting of 30.83%. Casdin Partners Master Fund, L.p. also owns 10,000,000 shares of MaxCyte Inc (MXCT) as of October 3, 2022, with a value of $39 Million and a weighting of 8.37%. The other 6 stocks Absci Corp (ABSI) , Verve Therapeutics Inc (VERV) , 2seventy bio Inc (TSVT) , Decibel Therapeutics Inc (DBTX) , Constellation Pharmaceuticals Inc (CNST) , Fulcrum Therapeutics Inc (FULC) have a combined weighting of 13.76% among all his current holdings.
Latest Holdings of Casdin Partners Master Fund, L.p.
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
BLFS | BioLife Solutions Inc | 2023-10-19 | 8,707,165 | 25.04 | 218,027,412 |
LAB | Standard BioTools Inc | 2024-08-27 | 74,036,109 | 1.93 | 142,889,690 |
MXCT | MaxCyte Inc | 2022-10-03 | 10,000,000 | 3.88 | 38,800,000 |
ABSI | Absci Corp | 2021-07-26 | 7,718,593 | 3.82 | 29,485,025 |
VERV | Verve Therapeutics Inc | 2021-06-21 | 2,417,596 | 4.84 | 11,689,077 |
TSVT | 2seventy bio Inc | 2024-03-26 | 2,016,600 | 4.72 | 9,518,352 |
DBTX | Decibel Therapeutics Inc | 2021-02-17 | 1,121,421 | 4.91 | 5,506,177 |
CNST | Constellation Pharmaceuticals Inc | 2018-07-23 | 158,960 | 33.99 | 5,403,050 |
FULC | Fulcrum Therapeutics Inc | 2019-07-22 | 604,285 | 3.57 | 2,157,297 |
Holding Weightings of Casdin Partners Master Fund, L.p.
Casdin Partners Master Fund, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Casdin Partners Master Fund, L.p. has made a total of 9 transactions in BioLife Solutions Inc (BLFS) over the past 5 years, including 9 buys and 0 sells. The most-recent trade in BioLife Solutions Inc is the acquisition of 927,165 shares on October 19, 2023, which cost Casdin Partners Master Fund, L.p. around $10 Million.
According to the SEC Form 4 filings, Casdin Partners Master Fund, L.p. has made a total of 12 transactions in Standard BioTools Inc (LAB) over the past 5 years, including 12 buys and 0 sells. The most-recent trade in Standard BioTools Inc is the acquisition of 250,000 shares on August 27, 2024, which cost Casdin Partners Master Fund, L.p. around $547,500.
According to the SEC Form 4 filings, Casdin Partners Master Fund, L.p. has made a total of 3 transactions in MaxCyte Inc (MXCT) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in MaxCyte Inc is the sale of 735,786 shares on October 3, 2022, which brought Casdin Partners Master Fund, L.p. around $5 Million.
More details on Casdin Partners Master Fund, L.p.'s insider transactions can be found in the Insider Trading History of Casdin Partners Master Fund, L.p. table.Insider Trading History of Casdin Partners Master Fund, L.p.
- 1
Casdin Partners Master Fund, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Casdin Partners Master Fund, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Casdin Partners Master Fund, L.p. is -10.21%. GuruFocus also compares Casdin Partners Master Fund, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Casdin Partners Master Fund, L.p. within 3 months outperforms 7 times out of 21 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Casdin Partners Master Fund, L.p.'s insider trading performs compared to the benchmark.
Performance of Casdin Partners Master Fund, L.p.
Casdin Partners Master Fund, L.p. Ownership Network
Casdin Partners Master Fund, L.p. Owned Company Details
What does BioLife Solutions Inc do?
Who are the key executives at BioLife Solutions Inc?
Casdin Partners Master Fund, L.p. is the 10 percent owner of BioLife Solutions Inc. Other key executives at BioLife Solutions Inc include Chief Tech. Officer & Sr. VP Aby J. Mathew , Chief Revenue Officer Garrie Richardson , and Vice President & Marketing Todd Berard .
BioLife Solutions Inc (BLFS) Insider Trades Summary
Over the past 18 months, Casdin Partners Master Fund, L.p. made 4 insider transaction in BioLife Solutions Inc (BLFS) with a net purchase of 1,135,630. Other recent insider transactions involving BioLife Solutions Inc (BLFS) include a net sale of 119,093 shares made by Aby J. Mathew , a net sale of 46,788 shares made by Todd Berard , and a net sale of 18,388 shares made by Sarah Aebersold .
In summary, during the past 3 months, insiders sold 27,537 shares of BioLife Solutions Inc (BLFS) in total and bought 0 shares, with a net sale of 27,537 shares. During the past 18 months, 368,891 shares of BioLife Solutions Inc (BLFS) were sold and 1,135,630 shares were bought by its insiders, resulting in a net purchase of 766,739 shares.
BioLife Solutions Inc (BLFS)'s detailed insider trading history can be found in Insider Trading Tracker table.
BioLife Solutions Inc Insider Transactions
Casdin Partners Master Fund, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Casdin Partners Master Fund, L.p.. You might contact Casdin Partners Master Fund, L.p. via mailing address: Walker House, 87 Mary Street, George Town E9 Ky1-9001.